n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, December 5th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

BTCS, Inc. (BTCS)

RedChip, PricelessPenny, SmallCapVoice, 1-2-3 Stock Alerts, Money Morning, Fortune Stock Alerts, Penny Stock Circle, Value Penny Stocks, StockMarketQuote.us, StockMister, PennyPro, Stock Commander, HotStockProfits, AddictivePennyStocks, Bullseyestox, PennyStockRumors.net, PennyStocks Forever, and TheMicrocapNews reported on BTCS, Inc. (BTCS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BTCS, Inc. is a blockchain technology company based in Silver Spring, Maryland. The Company is an early entrant in the Digital Asset market. It is also one of the first U.S. publicly traded companies engaged with Digital Assets and blockchain technologies. The Company has a record of accomplishment of accurate digital asset trend prediction. Blockchains are distributed public ledgers that can fundamentally influence all industries around the world that require trust and rely on or use record keeping.

A blockchain is secured and maintained by a network of specialized servers (nodes) internationally. All transactions are publicly available on a blockchain. Transactions undergo verification and confirmation by way of nodes worldwide before being added to a blockchain.

BTCS’ plan (subject to additional financing) is to create a portfolio of digital assets, such as bitcoin and other "protocol tokens", to provide investors a varied pure-play exposure to the bitcoin and blockchain industries. The Company’s intention is to acquire digital assets via open market purchases; and participate in initial digital asset offerings (or initial coin offerings).

In addition, BTCS may acquire digital assets through resuming its transaction verification services business (or mining) through outsourced data centers and earning rewards in digital assets by securing their respective blockchains. Furthermore, the Company is focusing on growth through acquisition.

This past August, BTCS announced it signed a non-binding Letter of Intent (LOI) to merge with Blockchain Global Limited (BCG), an Australian blockchain company.  BCG operates four different business lines. These include an institutional exchange platform, transaction verification services (bitcoin mining), a blockchain start-up accelerator, and a blockchain technology consultancy.

Recently, BTCS announced it secured $1,000,000 in financing. This includes $250,000 (59.38) in bitcoin. Mr Charles Allen, BTCS Chief Executive Officer, said, “This financing represents a major milestone in the ongoing evolution of our Company. With the opportunity in the burgeoning blockchain space is still in its infancy, our planned merger with Blockchain Global Ltd. (BGL) positions us with a diversified business model that sets the stage for market leadership globally, and this financing represents a strong commitment to move forward.”

In October, BTCS announced it closed on the remaining balance of its earlier announced financing that was co-led by Blockchain Global Ltd. (BGL). The Company received a total of $1.1 million from the sale of its Series C -1 Convertible Preferred Stock (the C-1) and Warrants.

BTCS, Inc. (BTCS), closed Tuesday's trading session at $0.1104, down 3.92%, on 14,989,016 volume with 1,330 trades. The average volume for the last 60 days is 15,473,678 and the stock's 52-week low/high is $0.0285/$0.578.

Digipath, Inc. (DIGP)

SmallCapVoice, SECFilings.com News, Otcstockexchange, Whisper from Wall Street, SmallCapStockPlays, The Wall Street Transcript, CFN Media Group, Promotion Stock Secrets, Cannabis Financial Network News, Wallstreetbuzz, DSR News, Investor News Source, StockRockandRoll, PennyStockLocks, TheMicrocapNews, AddictivePennyStocks, PricelessPennyStocks, PennyStockRumors.net, and Real Pennies reported earlier on Digipath, Inc. (DIGP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Digipath, Inc. is an independent cannabis testing and media organization. The Company supports the cannabis industry’s best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath’s two business units are Digipath Labs and TNM News Corp. Digipath is based in Las Vegas, Nevada.

The National Marijuana News (TNMNews) is the Company’s unbiased cannabis news site and talk radio show. Its emphasis is on the political, economic, medicinal, and cultural dimensions of the medicinal and recreational marijuana industry. Digipath Labs is the cannabis testing subsidiary of the Company.

Digipath Labs is working to set the industry standard for testing all types of cannabis-based products using Food and Drug Administration (FDA)-compliant laboratory equipment and proprietary Standard Operating Procedures (SOP) to ensure product safety and efficacy.

In 2015, Digipath opened its first state-of-the-art cannabis testing lab, Digipath Labs, in Las Vegas, Nevada. Its flagship cannabis analytical testing laboratory in Las Vegas helps safeguard patient safety and provide cannabinoid and terpenoid potency data that can be used to match specific products to medical conditions.

Digipath Labs has been chosen as the laboratory testing service provider for The Clinic Nevada, LLC. The Clinic has many retail and cultivation locations in Colorado and Illinois. The Clinic Nevada is a licensed cannabis cultivator, producer, and dispenser located in Las Vegas, Nevada. At present, Digipath tests products coming out of The Clinic Nevada's production facility branded as "The Lab".

This past September, Digipath announced that it entered into a joint venture (JV) with Mr. Don Ashley, an experienced real estate developer and cannabis entrepreneur, to establish and operate a cannabis testing laboratory in California. The JV, Humboldt Botanical, LLC, will conduct business under the name "Digipath Botanical Testing". It will launch Digipath's entry into the largest cannabis market in the U.S.

With this JV agreement, Mr. Ashley will contribute up to $2 million to fund the build-out and equipping of the testing laboratory. Digipath will be responsible for managing and supervising the daily operations of the laboratory.

The new testing laboratory will be part of a larger, three-building cannabis industrial park. The expectation is that the industrial park will include a research and development (R&D) facility, an oils/concentrate manufacturing center, a health and wellness center, a distribution and processing facility, a tissue culture nursery, a hemp clothing outlet, and coffee bistro.

Digipath, Inc. (DIGP), closed Tuesday's trading session at $0.28, down 1.93%, on 350,580 volume with 80 trades. The average volume for the last 60 days is 118,309 and the stock's 52-week low/high is $0.1305/$0.355.

First Choice Healthcare Solutions, Inc. (FCHS)

First Penny Picks, Marketbeat, 007 Stock Chat, PennyStockSpy, Greenbackers, StocksImpossible, TheMicrocapNews, and OTCBB Journal reported earlier on First Choice Healthcare Solutions, Inc. (FCHS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

First Choice Healthcare Solutions, Inc. (FCHS) engages in owning and operating multi-specialty (non-physician-owned) medical centers of excellence across the southeastern United States. The Company is one of the nation's only non-physician-owned, publicly traded healthcare services enterprises focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedic and Spine care. OTCQB-listed, FCHS is based in Melbourne, Florida.

The Company’s commitment is to deliver clinically superior, patient-centric care. Its flagship integrated platform presently administers over 100,000 patient visits each year and comprises First Choice Medical Group, The B.A.C.K. Center, and Crane Creek Surgery Center.

FCHS medical centers of excellence concentrate on treating patients in different specialties. These include Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management and related diagnostic and ancillary services.

First Choice Medical Group (Melbourne, Florida) is FCHS’s flagship multi-specialty medical center of excellence. First Choice Medical Group specializes in the delivery of musculoskeletal medicine and rehabilitative care with many quality-focused goals centered on enriching its patients’ care experience.

FCHS has expanded its portfolio of Medical Centers of Excellence in the Florida Space Coast area, with its Brevard Orthopaedic Spine & Pain Clinic, Inc., dba The B.A.C.K. Center. The B.A.C.K. Center is a foremost, advanced orthopaedic spine and pain practice in Brevard County, Florida. It centers on Spinal Care & Surgery; Non-Operative Spine Procedures; Chiropractic Services; Osteoporosis Care; Acupuncture; and Interventional Pain Management.

FCHS’s Crane Creek Surgery Center is an AAAHC accredited facility. Its commitment is to deliver premier, ambulatory surgical care in a convenient, comfortable outpatient environment. The 18,000-plus sq. ft. facility is in Melbourne, Florida within the Crane Creek Medical Center building. This building is also home to The B.A.C.K. Center.

Last month, FCHS announced that it signed a non-binding Letter of Intent (LOI) for the acquisition of a multi-site ancillary services business to expand its market presence. Regarding the LOI for an ancillary services business, it offers an expanded market presence via multiple locations, and additional revenue streams from ancillary modalities not now offered by the Company.

In addition, it offers the ability to manage a broader base of patient pre-and post-operative ancillary services. The anticipated incremental revenue is $7 to $9 million.

Chris Romandetti, FCHS President and Chief Executive Officer, stated, "We are pleased to have signed our letter of intent to acquire a complementary business, which if completed, will expand our footprint within our industry, and will also generate incremental revenue and offer additional revenue streams. We anticipate closing the transaction during the first quarter of 2018."

First Choice Healthcare Solutions, Inc. (FCHS), closed Tuesday's trading session at $1.20, down 7.69%, on 3,600 volume with 13 trades. The average volume for the last 60 days is 23,462 and the stock's 52-week low/high is $0.90/$1.75.

Liberty One Lithium Corp. (LRTTF)

ProcativeInvestors, OTC Markets, 4 Traders, and MarketWatch reported on Liberty One Lithium Corp. (LRTTF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Liberty One Lithium Corp. is a developing exploration company listed on the OTC Markets’ Group’s OTCQB. It concentrates on the acquisition and development of high grade lithium brine deposits. Lithium is an important component of batteries, which power everything from cars to smartphones, laptops, and power tools. The Company sees lithium as an opportunity to participate in the diversification and continued growth (and protection) of a strong global energy policy. Liberty One Lithium has its corporate office in Vancouver, British Columbia.

Liberty One Lithium’s initial prospects are in Argentina’s “Lithium Triangle” and Utah’s Paradox Basin. They are located in historic sources of high grade lithium-bearing brines. Historic resource indicates potential to produce huge volumes of brine on-site.

In Utah, the Company’s North Paradox property consists of 233 placer claims encompassing 4,480 acres located upon the Paradox Basin in Grand County, Utah, 15 kilometers west of the town of Moab, in southeastern Utah.

In Argentina, its Pocitos West prospect consists of greater than 39,000 acres (15,857 Ha) in the middle of the well-known lithium triangle. It is in the Pocitos Salar, Los Andes Department, Western Salta Province, Argentina.

Liberty One Lithium announced in June of this year the closing of a mineral option and joint venture (JV) agreement with Millennial Lithium Corp. (Vancouver, British Columbia). The agreement grants Liberty One Lithium the sole and exclusive right and option to acquire up to an 80 percent undivided beneficial right, title, and interest in the Pocitos West project in Argentina.

In August, Liberty One Lithium announced results from its geophysical survey at its Pocitos West property in Argentina. It detected a probable brine horizon extending throughout the entire 29 km length of its mining property, suggesting the potential for lithium to exist beneath much of the Company's 160 km2 licensed area.

In addition, the survey indicates that the depth of the conductive horizon is as much as 150 meters thick in several target locations. Liberty, via its operating partner Millennial Lithium, conducted a Vertical Electrical Soundings (VES) survey. VES detects variations in subsurface conductivity.

At the end of October, Liberty One Lithium advised that drilling began at its Pocitos West property in Northern Argentina. The Company stated that the operational team moved fast to secure and mobilize a drilling rig and all related equipment. With operations in progress, on-site determination by the team will measure initial findings from the brine samples at specific depths, as defined by geophysics and drill hole logging.

If warranted, the team may choose to case the primary well for monitoring, and drill an adjacent rotary/core hole for pumping tests. Upon the initial well being at depth and down-hole geophysics logging and depth-specific packer sampling are completed, the drilling equipment will be moved to the second target to undertake preliminary wide-area sampling of the salar basin characteristics.

Liberty One Lithium Corp. (LRTTF), closed Tuesday's trading session at $1.15, down 6.79%, on 571,306 volume with 521 trades. The average volume for the last 60 days is 2,216,863 and the stock's 52-week low/high is $0.3739/$1.95.

Agritek Holdings, Inc. (AGTK)

PennyPro, SmallCapVoice, CFN Media Group, Promotion Stock Secrets, and Cannabis Financial Network News reported on Agritek Holdings, Inc. (AGTK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Agritek Holdings, Inc. is a fully integrated, active cannabis real estate investor and branding consultant in the legal cannabis sector. The Company provides innovative technology and agricultural solutions for the medicinal and recreational cannabis industry. Established in 2010, Agritek Holdings is based in Miami, Florida. The Company has a satellite office in San Juan, Puerto Rico.

Agritek does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act. It does not intend to do so in the future.

Agritek owns property in Colorado approved for cultivation, and manufacturing capabilities through California partnerships. In addition, the Company owns several Hemp and cannabis brands for distribution.

Agritek’s brands are a premium positioned set of consumer brands for medical wellness and recreational use. Agritek owns a number of hemp and cannabis brands for distribution. These include MD Vapes, MicroDose Strips, and "Hemp Pops" and "California Premiums."

The Company’s solution is an integrated platform designed for commercialization in three high-value segments of the worldwide cannabis market – Real Estate, AGTK Brands/IP, and Infrastructure.

Agritek’s Colorado property is 80-Acres approved for cannabis cultivation or manufacturing facility in Pueblo, Colorado. Its Puerto Rico property is a 25,000-sq. ft. licensed cannabis cultivation and manufacturing facility. The Company’s Canada property is a cannabis friendly "Bud & Breakfast" concept. It is one hour from Quebec City. It is on 15-acres that includes nine guest rooms plus a separate detached grow facility.

Agritek Holdings announced this past April that it completed, and fully executed, a five-year operational and exclusive licensing agreement with a 25,000-sq. ft. and one of the largest approved cultivation facilities in San Juan, Puerto Rico.

With the five-year operational contract and licensing agreement, Agritek will receive revenue in the form of property rent, licensing fees on all vaporizer and edible brands, equipment and lighting rental and financing fees along with equity interest in the property.

Recently, Agritek Holdings announced that it is in the final stages of licensing and construction planning for its 80 acres in Pueblo, Colorado. The expectation is that the Company's new industrial Hemp and research facility and pod farm will produce medical grade CBD oil for research and the launch of multiple product lines. The initial grow pod has been delivered to the facility while waiting for final approvals for numerous licensees.

Agritek Holdings has received approvals from the State Department of Health to transfer its manufacturing and cultivation licenses for its operating partner 1919 Clinic to its new state-of-the-art, San Juan-based facility. The new facility contains 15,000 usable square feet, which will be the first vertically integrated cannabis operation in San Juan, Puerto Rico that will operate as a cultivation and manufacturing facility, and also a separate space that can be dedicated to a retail dispensary partner.

Last month, Agritek announced that it has agreed and entered into negotiations to purchase the surrounding 900 acres of its' existing 80 acre Hemp planned research site in Pueblo, Colorado. Agritek has now been given the first right and accepted the offer to purchase the surrounding 900 acres making it one of the largest operating Hemp research projects seeking approval by the state.

Agritek Holdings, Inc. (AGTK), closed Tuesday's trading session at $0.0136, down 2.86%, on 33,191,076 volume with 525 trades. The average volume for the last 60 days is 6,293,470 and the stock's 52-week low/high is $0.0094/$0.041.

Immune Therapeutics, Inc. (IMUN)

SeriousTraders, PennyStocks24, StockBomb, PennyTrader, PennyStockLocks, StocksToBuyNow, InvestorTrendz, OTCtipReporter, StockLockandLoad, and StockRockandRoll reported on Immune Therapeutics, Inc. (IMUN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Immune Therapeutics, Inc. is a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer. The Company is working to combat chronic, life-threatening diseases via the activation and modulation of the body's immune system utilizing its patented immunotherapy. Its proprietary technology, therapies, and patents include the treatment of a broad spectrum of cancers. Immune Therapeutics is headquartered in Orlando, Florida.

The design of the Company’s products and immunotherapy technologies are to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Immune Therapeutics most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes called opioid growth factor) and its Low Dose Naltrexone product (LDN) or Lodonal™. These have been shown to stimulate the immune system even in patients with advanced cancer.

The Company, in association with the College of Medicine Malawi, has started a clinical study with LDN for the prevention of cervical cancer. This is an open-label, multicenter study. The design of it is to determine the safety and acceptability of a single-visit approach to cervical cancer prevention in patients.

The Brewer Foundation in partnership with Immune Therapeutics arranged the funding for the trial and the donation of the Wallach LL100 Cryosurgical system needed to run the trial and treat patients.

This past September, Immune Therapeutics announced that it entered into an exclusive agreement with Kenya-based Omaera Pharmaceuticals, Ltd. This agreement is for the sale and distribution of Lodonal™, valued at a minimum of $31 million in revenues over three years.

With the agreement, Omaera Pharmaceuticals will supply Lodonal to patients exclusively in Kenya. Immune Therapeutics will sell Lodonal to Omaera at a rate of $0.65 per pill, or $19.50 per carton.

It necessitates a minimum purchase commitment of more than one million pills in the first six months; more than 3.6 million pills in the second half of the first year; and 14.4 million and 28.8 million in the second and third years, respectively.

The Omaera Pharmaceuticals territory includes the Republic of Kenya, the Republic of Uganda, the United Republic of Tanzania, the Republic of Burundi, and the Republic of Rwanda.

Immune Therapeutics, Inc. (IMUN), closed Tuesday's trading session at $0.0159, down 15.87%, on 4,233,538 volume with 99 trades. The average volume for the last 60 days is 802,035 and the stock's 52-week low/high is $0.013/$0.0927.

PharmaCyte Biotech, Inc. (PMCB)

OTCJournal, InvestorPlace, Goldman Small Cap Research, Damn Good Penny Picks, Penny Picks, Wall Street Corner, Stock Market Media Group, Penny Stock General, PennyStockInformer, PennyStockLaboratory, SmallCapNetwork, Cannabis Financial Network News, BUYINS.NET, MyBestStockAlerts, Darth Trader, Fast Money Alerts, Penny Stock Beats, Stock Shock and Awe, and The Stock Psycho reported earlier on PharmaCyte Biotech, Inc. (PMCB), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. concentrates on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This inventive and patented technology is being used as a platform upon which treatments for many kinds of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. A clinical stage biotechnology company, PharmaCyte Biotech has its headquarters in Silver Spring, Maryland. The Company lists on the OTCQB.

Additionally, PharmaCyte Biotech is working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other kinds of solid cancerous tumors. Its treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form.

These capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.

The Company is also developing treatments for cancer based upon chemical constituents of the Cannabis  plant, called cannabinoids. It is studying ways to exploit the benefits of Cell-in-a-Box®  technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects typically associated with cancer treatments.

The live-cell encapsulation technology that PharmaCyte Biotech utilizes is a way to enclose living cells in protective “cocoons” around the size of the head of a pin. It encapsulates living cells, not drugs.  Each capsule can enclose about 10,000 cells. This number can vary depending upon the size of the cells encapsulated. The Company is advancing its new treatment for pancreatic cancer into the clinic in the United States, with study sites in Europe and Australia.

Recently, PharmaCyte Biotech announced that its research partner, the University of Northern Colorado (UNC), identified an organism whose genome contains the genetic code for production of an enzyme capable of activating a cannabinoid prodrug into its active cancer-killing form.

Mr. Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer, said, “We are pleased that UNC has taken us one step closer to developing cannabinoid-based therapies to combat cancer utilizing our proprietary Cell-in-a-Box® live-cell encapsulation technology.”

Last week, PharmaCyte Biotech reported that Eurofins Lancaster Laboratories successfully completed its independent growth evaluation of the cells that PharmaCyte will use in its Cell-in-a-Box®-based pancreatic cancer therapy. This is a significant step in preparing for PharmaCyte Biotech’s pancreatic cancer clinical trial. Eurofins Lancaster Laboratories is a foremost Contract Manufacturing Organization that PharmaCyte chose to prepare its Master Cell Bank (MCB).

This important step in the overall product development process has been attained utilizing the optimal cell culture medium that has only recently become available. The growth evaluation of the cells is a necessary pre-step to produce the MCB, which is required to comply with Food and Drug Administration (FDA) guidelines.

PharmaCyte Biotech, Inc. (PMCB), closed Tuesday's trading session at $0.068, up 19.53%, on 6,881,950 volume with 503 trades. The average volume for the last 60 days is 2,764,373 and the stock's 52-week low/high is $0.0302/$0.1689.

graphic

The QualityStocks
Company Corner

graphic
graphic

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.74, up 12.12%, on 928,825 volume with 503 trades. The stock’s average daily volume over the past 60 days is 125,559 and its 52-week low/high is $0.40/$2.75.

ChineseInvestors.com, Inc. (OTCQB: CIIX), the premier financial information website for Chinese-speaking investors, announced today that it has entered into an agreement with Blockchain BTM, LLC to host a Bitcoin ATM at its San Gabriel, California office with plans to expand to serve other Chinese Communities throughout the United States. The Bitcoin ATM, located in the lobby of the Company's offices in the highly trafficked San Gabriel Hilton Plaza, is open from 9 a.m. to 6 p.m., Monday through Friday, making it convenient and easy to purchase Bitcoin.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc. Announces That it has Entered Into an Agreement With Blockchain BT, LLC to Host a Bitcoin ATM at its San Gabriel, California Office With Plans to Expand to Serve Other Chinese Communities Throughout the United States

ChineseInvestors.com, Inc. (CIIX) OptHemp Line Achieves a Big Hit with Product Launch

CannabisNewsBreaks – ChineseInvestors.com, Inc.’s (CIIX) CBD Biotechnology Enterprise Partners with Chinese Beauty Influencer to Launch CBD Magic Hemp Series Skincare Line on Taobao

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.63, up 6.91%, on 1,671,513 volume with 686 trades. The stock’s average daily volume over the past 60 days is 834,761, and its 52-week low/high is $0.09/$0.72.

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF) NetworkNewsWire Editorial Coverage: As more Canadians than ever suffer chronic pain, the chase is on to find novel therapeutic approaches to effectively manage their conditions. In fact, BMC Public Health estimates that 20% of adults on a global level suffer from chronic pain while 10% are newly diagnosed every year. In Canada, chronic pain affects 1.5 million people. As national and worldwide numbers in pain diagnoses continue to rise, innovators in the cannabis industry are developing promising therapies to address this growing market. 

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Purified Cannabinoids Open New Opportunities in Pain Management

InMed to Present at Cannabis-Based Science & Medicine Conference

NetworkNewsWire Announces Publication Featuring Innovative Approach to Cannabis R&D

Carl Data Solutions Inc. (CSE:CRL) (FSE:7C5) (OTC:CDTAF)

The QualityStocks Daily Newsletter would like to spotlight Carl Data Solutions Inc. (CDTAF). Today, Carl Data Solutions Inc. closed trading at $0.373, up 4.07%, on 393,638 volume with 203 trades. The stock’s average daily volume over the past 60 days is 3,164 and its 52-week low/high is $0.2015/$0.3984.

Carl Data Solutions Inc. (CSE:CRL) (FSE:7C5) (OTC:CDTAF) continues its expansion into the solid waste management sector of the Industrial IoT (IIoT) and has signed a Letter of Intent for an upcoming pilot project. Globally, the market for waste management is expected to grow to around $562 billion USD by 2020. In cooperation with Peak Disposal Services Inc. ("Peak Disposal"), Carl Data is developing an industrial-grade solid waste management monitoring system.

Carl Data Solutions Inc. (CSE: CRL) (FSE: 7C5) (OTC: CDTAF), a developer of Big-Data-as-a-Service ("BDaaS")-based solutions for data integration, business intelligence and Industrial Internet-of-Things ("IIoT") applications, is headquartered in Vancouver, British Columbia, Canada. The company's BDaaS enterprise applications platform provides custom cloud-based collection, storage, monitoring and advanced analysis of any data source of any size or complexity.

Carl Data Solutions provides smart, real-time solutions for industries that routinely face an overload of data. The company's team of dedicated data scientists and application developers build environmental monitoring and modeling technology that collects, connects and manages data to protect industrial and infrastructure assets. As experts in data collection, storage, analytics and reporting, the team is experienced in the complex issues facing governmental and industrial sectors and is well positioned in key IIoT market segments to offer customized solutions.

Among the benefits of CARL's Big Data solutions: turning vast quantities of information into meaningful, actionable insights for any business; gathering data from multiple sources and monitoring in real-time, allowing for better decision making and forecasting; identifying business performance issues or operational efficiencies quickly and accurately for cost and time savings; and, mitigating risks with predictive analytic capabilities to manage unplanned events.

The company's most recent acquisitions include:

  • FlowWorks, a SaaS-based monitoring, data collection, alarming, modeling and reporting system utilized by major clients across North America.
  • abEmbedded Systems Ltd., a Mesh and LoRa advanced telemetry platform using industrial grade custom sensors and data loggers operating in over 250 pump stations across North America.
  • Extend to Social (ETS), a social media application that adds a deep analytics layer that provides clients with valuable insights for new marketing campaigns plus behavioral characteristics for customer service, operations and product development.

Carl Data Solutions provides scalable solutions that integrate public data, Smart IIoT and legacy devices that provides real-time alarming and data analysis. Development of a framework that manages large volumes of diverse types of both structured and unstructured data, stored in an unlimited cloud-based platform that offers advanced analytics features for deeper data insights, provides instant analysis of any inbound data. CARL's applications locate relationships and patterns, which can then predict the probability of specific events, providing valuable insights applicable to any entity dealing with operational issues and regulatory requirements. Both technical and business users are able to quickly and easily understand the impact of environmental events on infrastructure through a comprehensive suite of dashboards, geographic information systems and graphic tools.

The company's predictive analytics, machine learning, and web-based applications can be utilized for waste and storm water management, in the protection of oil and gas pipeline stream crossings, and by hydro-electric dams and toxic tailing ponds, among other industrial uses. The global industrial IoT market alone is expected to reach USD $933.62 billion by 2025, according to a new report by Grand View Research, Inc. (http://nnw.fm/yLBv0). Businesses are seeking new operating models that will increase overall productivity, enhance operational efficiency, improve visibility and reduce complexities of various processes – all of which are targets of Carl's Data Solutions.

An expert management team is at the company core with Greg Johnston leading as its president, CEO and director. Johnston is an experienced technology professional with a proven track record of leadership success within both large multinational corporations and small start-up technology ventures. Disclaimer

Carl Data Solutions Inc. Blog

Carl Data Solutions Inc. News:

Carl Data Solutions Signs Letter of Intent for Solid Waste Management Pilot

Carl Data Solutions Completes Acquisition of Assets of AB Embedded Systems

Carl Data Solutions Announces Closing of Private Placement

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.106, off by 14.17%, on 36,648,805 volume with 2,119 trades. The stock’s average daily volume over the past 60 days is 7,647,222, and its 52-week low/high is $0.01/$0.415.

SinglePoint, Inc. (OTC:SING) today announces a joint venture relationship with Smart Cannabis Corporation (OTC:SCNA) (www.smartcannabis.com) in which SinglePoint will license and market Smart Cannabis’ SMART APP, an industry specific application that enables cultivators to control entire operations from a mobile device. The SMART APP is leading the way in efficiently cultivating cannabis through the introduction of IoT technology (Internet of Things) to greenhouses.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint and Smart Cannabis Corp. Sign Joint Venture to Integrate, Distribute ‘SMART APP’ for Cannabis Businesses

CannabisNewsWire Announces Publication Discussing Payment Processing Solutions for the Cannabis Marketplace

AppSwarm and SinglePoint Finalize Plans for Cannabis and Bitcoin Focused Applications and Technology

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.7188, off by 1.22%, on 521,348 volume with 334 trades. The stock’s average daily volume over the past 60 days is 97,287 and its 52-week low/high is $0.171/$0.7401.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), announces its research arm, Cannevert Therapeutics Ltd. has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. IMC will provide Cannevert with specific cannabis strains for upcoming human studies in the US territory.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

NetworkNewsWire Announces Publication on Investment Opportunities Created by Ongoing R&D of Medical Cannabis

Veritas Pharma Appoints of BC's "Top 40 Under 40" Robert Dawson – a Highly Regarded Marketing & Innovation Expert to Its Advisory Board

Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.374, up 33.62%, on 42,225 volume with 21 trades. The stock’s average daily volume over the past 60 days is 60,799, and its 52-week low/high is $0.131/$3.99.

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

NetworkNewsWire Announces Publication Highlighting Disruptive Business Models in Growing Telemedicine Sector

NetworkNewsWire Announces Publication Highlighting Revolutionary Solutions in the Telemedicine Market

Medical Innovation Holdings to be Featured on National Radio Telecasted Tuesday October 24th, 2017 at 10AM ET on Beasley Broadcasting

Cache Elite Inc. (ILUS)

The QualityStocks Daily Newsletter would like to spotlight Cache Elite Inc. (ILUS). Today, Cache Elite Inc. closed trading at $0.005645, up 25.44%, on 16,873 volume with 4 trades. The stock’s average daily volume over the past 60 days is 210,882 and its 52-week low/high is $0.0021/$0.065.

Cache Elite Inc. (ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world's airlines through Google's ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company's software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry. Disclaimer

Cache Elite Inc. Blog

Cache Elite Inc. News:

Cache Elite Inc. (ILUS) Engages NetworkNewsWire for Corporate Communications Solutions

Cache Elite Inc. (ILUS) is “One to Watch”

A New Audio Interview with Cache Elite, Inc. CEO, Derrick McWilliams, is now at SmallCapVoice.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Trader Power News
(CUR) +175.89%

2.

StockMarketWatch
(RVNC) +33.65%

3.

QualityStocks
(MIHI) +33.62%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251